MassDevice Q&A: John McDonough

August 4, 2009 by Joe Nowlan

The T2 Biosystems CEO on the company's innovative, miniaturized diagnostic tool, the importance of de-risking before you hit the fundraising trail and why the U.S. intelligence community is interested in T2's technology.

John McDonough, CEO of Cambridge, Mass.-based T2 Biosystems Inc., is an optimist.

Bullish on his 22-employee company's prospects (the estimated $40 billion diagnostics market might have something to do with that), McDonough (far left in the picture at right) spoke with MassDevice about the technology behind T2's diagnostic device, which uses a miniaturized version of a magnetic resonance imaging machine to deliver near-instant test results from just about any blood, urine or saliva sample.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Comments

Features

The FDA is ramping up its cybersecurity labs and may start rejecting insecure technologies sooner than you think.

Transcend Medical CEO Brian Walsh tells MassDevice.com why his company's CyPass micro-stent is poised to revolutionize the treatment of glaucoma.

Integrity Applications looks beyond optical sensors with its GlucoTrack Model DF-F, which uses ultrasonic, electromagnetic and thermal technology to measure physiological changes associated with blood glucose levels.

Former NBA player Jonathan Bender tries his hand at entrepreneurship, aiming to bring the physical therapy device he invented to the U.S. market.

Battelle engineering manager Melissa Masters tells MassDevice.com how insights ranging from national security to aeronautics can inform the creation of disruptive new medical devices.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp